Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4−/−: A double-blind, randomized, placebo-controlled crossover trial

• Published in: Clinical nutrition (Edinburgh, Scotland) Scotland), 2020-07, Vol.39 (7), p.2092-2105
• Main Authors: Xu, Qing, Zhang, Yong, Zhang, Xinsheng, Liu, Lu, Zhou, Bo, Mo, Rui, Li, Yan, Li, Huizi, Li, Feng, Tao, Yang, Liu, Yinghua, Xue, Changyong
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Apolipoprotein E; Cognition; Medium-chain triglyceride; Metabolomics
• ISSN: 0261-5614; 1532-1983
• DOI: 10.1016/j.clnu.2019.10.017

Previous clinical and animal studies suggested that medium-chain triglycerides (MCT) might be an alternative energy substrate for the brain and might benefit patients with Alzheimer's disease (AD), but the clinical evidence is not substantial or totally convincing. To investigate the effects of MCT on cognitive ability in patients with mild to moderate AD and explore the changes in peripheral blood metabolomics. A double-blind, randomized, placebo-controlled crossover study was undertaken in 53 mild to moderate AD patients. Participants were randomized between two sequences (placebo followed by MCT or MCT followed by placebo) and took MCT jelly or placebo jelly (canola oil) by mouth three times daily (total daily fat dose: 17.3 g MCT, or 19.7 g canola oil) for 30 days per phase. The primary outcome was cognition as measured by the Alzheimer's Disease Assessment Scale–Cognitive Subscale, Chinese version (ADAS-Cog-C). The secondary outcome was self-care as measured by the activities of daily living scale (ADL) and changes in plasma metabolites. This study showed a significant (p  0.05). The concentrations of TC, HDL-C, β-hydroxybutyrate and acetoacetate were significantly higher in the MCT group than in the placebo group (p